Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Adsorbed diphtheria-purified pertussis-tetanus combined vaccine - BIKEN/Mitsubishi Tanabe Pharma

Next Previous
Drug Profile

Adsorbed diphtheria-purified pertussis-tetanus combined vaccine - BIKEN/Mitsubishi Tanabe Pharma

Alternative Names: BK 1301; DTaP vaccine - BIKEN/Mitsubishi Tanabe Pharma; Tribik

Latest Information Update: 22 Aug 2017

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Mitsubishi Tanabe Pharma Corporation; Research Foundation for Microbial Diseases of Osaka University
  • Developer BIKEN; Mitsubishi Tanabe Pharma Corporation
  • Class Bacterial vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Diphtheria; Pertussis; Tetanus

Most Recent Events

  • 30 Apr 2015 Mitsubishi Tanabe Pharma files sNDA for stage 2 vaccination in prophylaxis of patients with Diphtheria, Pertusis and Tetanus in Japan (Mitsubishi Tanabe Pharma pipeline, May 2015)
  • 01 Aug 2014 Mitsubishi Tanabe Pharma completes a phase III trial in Diphtheria, Pertussis and Tetanus (Prevention, In adolescents) in Japan (NCT02118961)
  • 30 Apr 2014 Mitsubishi Tanabe Pharma in collaboration with the Research Foundation for Microbial Diseases of Osaka University initiates phase-III clinical trials in Pertussis (Prevention, In adolescents) in Japan (SC) (NCT02118961)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top